There can't be many biotechs on Nasdaq with a lower...

There can't be many biotechs on Nasdaq with a lower capitalisation than Vaxart. It's been deservedly punished by association with Aviragen. And it still has a couple of execs and some board members from Avir.

But I love the way biotechs explode on good news over there - not 25% but 250%

So, I've looked at it again despite you all telling me not to.

There's only one other small company in the same space which uses salmonella as their carrier. They aren't looking at norovirus or influenza or rsv.

And their influenza study was actually pretty positive and the noro antibodies were also pretty good.

Gulp.